Fortis Healthcare Q4 Review - Omicron Dents Performance: ICICI Securities

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Securities Report.Fortis Healthcare Ltd.’s Q4 FY22 performance was below our estimates with Omicron wave impacting hospitalisation in the country. Revenues grew 10.0% YoY to Rs 13.8 billion (our estimate: Rs 14.8 billion) with hospitals and SRL (diagnostics) growing 6.0% and 37.7% YoY respectively. Ebitda margin stood at 16.1% (down 350 bps QoQ) versus our estimate of 19.0%. We expect Fortis Healthcare to continue its growth trajectory in the ensuing quarters driven by an increasingly normalising environment. Management has taken steps to reduce personnel and selling, general and administrative costs, benefits of which have been visible in the past few quarters. We remain positive on growth recovery, cost optimisation efforts and potential operating leverage. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Fortis Healthcare Q4 Review - Omicron Dents Performance: ICICI Securities

Fortis Healthcare Q4 Review - Omicron Dents Performance: ICICI Securities

Choose a plan